Loading
Life sciences · Phase 1 Trial
ClinicalTrials.gov · November 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 1 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07291232). This is a study registration, not published results. Lead sponsor: AbbVie. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 80 participants (ACTUAL). Conditions: Obesity. Interventions: DRUG: ABBV-295; DRUG: Placebo. Primary outcome measures: Number of Participants with Adverse Events (AEs) , Up to approximately 194 days; Number of Participants with Abnormal Change From Baseline in Vital Sign Measurements , Up to approximately 194 days; Number of Participants with Change from Baseline in Electrocardiogram (ECG) , Up to approximately 194 days; Number of Participants with Abnormal Change in Clinical Laboratory Test Results Like Hematology will be Assessed , Up to approximately 194 days; Maximum Observed Plasma Concentration (Cmax) of ABBV-295 , Up to approximately 194 days; Time to Cmax (Tmax) of ABBV-295 , Up to approximately 194 days; Trough plasma concentration (Ctrough) of ABBV-295 , Up to approximately 194 days; Apparent terminal phase elimination rate constant (BETA) of ABBV-295 , Up to approximately 194 days; Terminal phase elimination half-life (t1/2) of ABBV-295 , Up to approximately 194 days; Area under the plasma concentration-time curve (AUC) of ABBV-295 , Up to approximately 194 days; Area under the plasma concentration-time curve over the dosing interval (AUCtau) of ABBV-295 , Up to approximately 194 days; Dose Normalized Cmax of ABBV-295 , Up to approximately 194 days; Dose Normalized AUC of ABBV-295 , Up to approximately 194 days; Incidence of Anti-Drug Antibodies (ADAs) , Up to approximately 194 days; Percent Change in Body Weight From Baseline , Up to approximately 194 days. Brief summary: This study is to assess adverse events, change in body weight and pharmacokinetics in adult participants with obesity receiving ABBV-295 subcutaneous injections or matching placebo.